Hansoh Pharmaceutical Group Company Ltd

Hansoh Pharmaceutical Group's capital structure and liquidity position are not fully assessable due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's valuation snapshot does not provide sufficient data to evaluate its liquidity position or capital structure in detail.

In terms of profitability, Hansoh Pharmaceutical Group's financial performance is not fully quantifiable due to the lack of detailed financial metrics. The company's return on invested capital (ROIC) and other profitability indicators are not available in the current dataset, making it difficult to compare its performance against industry benchmarks or cohort medians.

The company's revenue is primarily concentrated in the domestic Chinese market, with no detailed breakdown of geographic exposure or segment performance provided in the available data. This lack of segmentation data limits the ability to assess the company's diversification and exposure to regional economic conditions.

Hansoh Pharmaceutical Group's growth trajectory is not clearly defined in the available data. The company's outlook for the current and next fiscal years is not quantified, and there are no numeric deltas provided to assess its revenue growth or contraction. Analysts have provided a mean price target of 45.88 CNY, with a median of 45.70 CNY, indicating a generally positive sentiment among analysts.

The company's risk profile is characterized by low dilution potential and an inability to assess liquidity risk due to the absence of balance-sheet data. The risk assessment does not identify any significant financial or operational risks, but the lack of going-concern language in the source documents raises some uncertainty about the company's long-term viability.

Recent events and filings for Hansoh Pharmaceutical Group are not detailed in the available data. There are no recent transcripts or filings provided that would indicate significant corporate developments, strategic shifts, or regulatory changes that could impact the company's operations or financial performance.

Revenue ¥15.03B, +22,6% YoY; Operating income +28,7% YoY.

• ▍Revenue ¥15.03B, +22,6% YoY
• ▍Operating income +28,7% YoY
• ▍Net income +27,1% YoY
• ▍Free cash flow +44,8% YoY
• ▍Net margin 37.0%

Revenue ¥12.26B, +21,4% YoY; Operating income +32,9% YoY.

• ▍Revenue ¥12.26B, +21,4% YoY
• ▍Operating income +32,9% YoY
• ▍Net income +33,4% YoY
• ▍Free cash flow −10,8% YoY
• ▍Net margin 35.7%

Revenue ¥10.10B, +7,7% YoY; Operating income +27,5% YoY.

• ▍Revenue ¥10.10B, +7,7% YoY
• ▍Operating income +27,5% YoY
• ▍Net income +26,9% YoY
• ▍Free cash flow +42,6% YoY
• ▍Net margin 32.4%

Revenue ¥9.38B, −5,6% YoY; Operating income −10,3% YoY.

• ▍Revenue ¥9.38B, −5,6% YoY
• ▍Operating income −10,3% YoY
• ▍Net income −4,8% YoY
• ▍Free cash flow −9,6% YoY
• ▍Net margin 27.5%

Revenue ¥9.94B; Operating income ¥3.35B.

• ▍Revenue ¥9.94B
• ▍Operating income ¥3.35B
• ▍Net margin 27.3%